The estimated Net Worth of Kenneth T. Mills is at least $24.5 Milión dollars as of 8 August 2024. Mr. Mills owns over 36,316 units of Regenxbio Inc stock worth over $5,647,701 and over the last 9 years he sold RGNX stock worth over $12,738,759. In addition, he makes $6,147,270 as President, Chief Executive Officer a Executive Director at Regenxbio Inc.
Kenneth has made over 58 trades of the Regenxbio Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 36,316 units of RGNX stock worth $30,869 on 8 August 2024.
The largest trade he's ever made was exercising 150,000 units of Regenxbio Inc stock on 11 January 2018 worth over $127,500. On average, Kenneth trades about 19,309 units every 43 days since 2015. As of 8 August 2024 he still owns at least 444,351 units of Regenxbio Inc stock.
You can see the complete history of Mr. Mills stock trades at the bottom of the page.
Kenneth T. Mills serves as President, Chief Executive Officer, Executive Director of the Company. He has been our President, Chief Executive Officer and Director since March 2009. Mr. Mills was with FOXKISER, most recently as a Partner, from January 2007 to January 2015. Mr. Mills was previously the Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, a life sciences company, from January 2004 to December 2006 and was part of the original management team that established the company’s operations and financing strategy. From March 1997 to December 2003, Mr. Mills was employed at IGEN, a biotechnology company, where he served as Director of Business Development up through the company’s acquisition by Roche. Mr. Mills received an S.B. in Chemistry from the Massachusetts Institute of Technology. Mr. Mills’ qualifications to continue to serve as a member of the Board include his extensive experience as an executive in the gene therapy and biotechnology industries, including as President and Chief Executive Officer of our Company, his prior service as a senior-level executive in both early stage and mature biotechnology companies and his demonstrated business judgment.
As the President, Chief Executive Officer a Executive Director of Regenxbio Inc, the total compensation of Kenneth Mills at Regenxbio Inc is $6,147,270. There are no executives at Regenxbio Inc getting paid more.
Kenneth Mills is 45, he's been the President, Chief Executive Officer a Executive Director of Regenxbio Inc since 2009. There are 19 older and no younger executives at Regenxbio Inc. The oldest executive at Regenxbio Inc is Allan Fox, 72, who is the Chairman of the Board.
Kenneth's mailing address filed with the SEC is C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.
Over the last 9 years, insiders at Regenxbio Inc have traded over $44,148,392 worth of Regenxbio Inc stock and bought 175,000 units worth $3,850,000 . The most active insiders traders include Llc Fmr, Argeris N Karabelas a Edgar Engleman. On average, Regenxbio Inc executives and independent directors trade stock every 15 days with the average trade being worth of $238,185. The most recent stock trade was executed by Argeris N Karabelas on 3 September 2024, trading 10,000 units of RGNX stock currently worth $37,600.
regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.
Regenxbio Inc executives and other stock owners filed with the SEC include: